Polyvalent Vaccine-KLH Conjugate + Opt-821 Given in Combination With Bevacizumab

NACompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

October 31, 2010

Primary Completion Date

September 30, 2017

Study Completion Date

September 30, 2017

Conditions
Fallopian Tubes CancerOvarian CancerPeritoneal Cancer
Interventions
BIOLOGICAL

bevacizumab and the polyvalent vaccine-KLH conjugate + OPT-821

A maximum of 6 doses of the polyvalent-KLH vaccine and OPT-821 will be administered to each patient as per the schedule. Bevacizumab will be administered once every two weeks until week 11 and then once every three weeks according to the schedule. When the 6 vaccinations of the polyvalent-KLH vaccine +OPT821 are completed, patients may still continue to receive bevacizumab on the once every three week schedule.

Trial Locations (1)

10065

Memorial Sloan-Kettering Cancer Center, New York

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER